GENFIT: Combined Shareholders’ Meeting of November 27, 2019 – Availability of Preparatory Documents
October 21 2019 - 4:15PM
GENFIT: Combined Shareholders’ Meeting of November 27, 2019 –
Availability of Preparatory Documents
GENFIT: Combined Shareholders’ Meeting of
November 27, 2019 – Availability of Preparatory
Documents
Lille (France), Cambridge
(Massachusetts, United States), October 21, 2019 –
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, today announced that it
published in October 21, 2019’s French legal announcements bulletin
(Bulletin des Annonces Légales Obligatoires) its convening notice
to the Combined Shareholders’ Meeting to be held on Wednesday,
November 27 2019, at 2:30pm, at the Company’s headquarters, located
Parc Eurasanté, 885 avenue Eugène Avinée in Loos (59120),
France.
Management will provide an update on the
Company’s activities over the last few months.
All documentation regarding this Shareholders’
Meeting is available to shareholders in accordance with existing
regulations, and is available on the Company’s website, in the
documentation center
(https://ir.genfit.com/financial-information/shareholders-meeting).
Documents listed in Article R.225-83 of the
French commercial code are available to shareholders in accordance
with existing regulations.
For this Shareholders’ Meeting, the Company will
allow shareholders to send their voting instructions via Internet
through the VOTACCESS platform. A tutorial to familiarize
shareholders with this new tool for online voting is available in
the documentation center.
Shareholders are invited to contact the
toll-free (France only) number starting Tuesday, October 22, 2019,
with any questions regarding how to participate in the Meeting:
0800 940 651.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial in PBC later this year following its positive
Phase 2 results. As part of GENFIT’s comprehensive approach to
clinical management of NASH patients, the company is also
developing a new, non-invasive and easy-to-access blood-based in
vitro diagnostic test to identify patients with NASH who may be
appropriate candidates for drug therapy. With facilities in Lille
and Paris, France, and Cambridge, MA, USA, the Company has
approximately 160 employees. GENFIT is a public company listed on
the Nasdaq Global Select Market and in compartment B of Euronext’s
regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Combined Shareholders’ Meeting of November 27, 2019 –
Availability of Preparatory Documents